Explore psychedelic drug development via our Q1'25 🎯 Bullseye Chart.

Champignon Brands

CSE: SHRM | OTC: SHRMF | FWB: 496

Champignon Brands is a publicly-traded, research-driven company active in the formulation and production of a variety of psychedelic medicines and products.

The Company has been subject to a Continuous Disclosure Review by the BC Securities Commission, and as such SHRM shares are currently under a Cease Trade Order.

[mstock id="3014"]

[mstock id="3015"]

Exclusive Interview

We spoke with Dr. Roger McIntyre, CEO of Champignon Brands, about his immediate and future plans for the company…

Latest News

Champignon Brands Changes Name to Braxia Scientific to Reflect the Integration of Ketamine and Psychedelic Clinics and its Research and Development Priorities

May 3, 2021

Champignon Brands Announces Revocation of Cease Trade Orders

April 22, 2021

Champignon Brands Announces Filing of Listing Statement

March 26, 2021

Champignon Brands to Restate Financial Statements and MD&A has Prepared CSE Listing Statement

February 17, 2021

Dr. Roger McIntyre Announces Changes to the Board of Champignon Brands Inc.

February 4, 2021

Champignon Brands’ Canadian Rapid Treatment Center of Excellence Opens First Community-Based Centre in Ottawa to Provide Ketamine Treatment for Adults With Depression

January 25, 2021

Join our Newsletter

Get the latest Company updates delivered to straight to your inbox.

Behind the Scenes of the “Psychedelic Renaissance” at SXSW 2025March 14, 2025
A recap of our discussion at SXSW 2025, which featured Graham Pechenik, Shayla Love, Jane Hu, and Josh Hardman and explored the changing face of psychedelic companies, the role of journalism in the field, predictions for the next five years, and much more.
Inside the World’s Most Active Psychedelic Therapy Site: A Conversation with Sunstone TherapiesMarch 12, 2025
Psychedelic Alpha’s Josh Hardman sits down with Sunstone Therapies co-founders Manish Agrawal and Kim Roddy to tease out their learnings from delivering hundreds of psychedelic therapy sessions at their purpose-designed facility.
Pα+ Psychedelic Bulletin #190: ‘Europe’s Most Feared Investor’ Teams Up with Musk Associate to Fund Lykos TherapeuticsMarch 6, 2025
‘Europe’s Most Feared Investor’ Teams Up with Musk Associate to Fund Lykos Therapeutics • Risk-Off or Reality Check? Psychedelic Stocks Slump After RFK Jr. Surge • Beckley Wraps Enrolment for Phase 2b Study of 5-MeO-DMT in Treatment-Resistant Depression • PATH Caucus RFI Submissions Roll In • Australian VA Mulls Funding Psychedelic Therapy • First Sponsored LSD Trial in the UK • and more...
A Rundown of Colorado’s Natural Medicine ProgramMarch 5, 2025
Now that the rules for Colorado’s regulated psychedelics program are set and license applications are open, Healing Advocacy Fund’s Colorado Director Tasia Poinsatte provides a brief, straightforward overview of the program and its key regulations.
Forging a Path to Access: Congressmen Correa and Bergman on the Future of Psychedelics in the U.S.March 4, 2025
Josh Hardman sits down with Congressmen Lou Correa and Jack Bergman to discuss their psychedelics-focused Congressional Caucus. They talk about the initiative’s progress to date, what it looks like to muster support for psychedelics in Washington in light of FDA’s MDMA rejection, and what the new U.S. administration means for their work and the field more broadly.

Psychedelic Alpha

Psychedelic Alpha is an independent newsletter and community that strives to empower a diverse constellation of individuals and organisations with the knowledge, network and nuance to make an impact within the field of psychedelic medicine and beyond

Quick Links

Newsletter

Insights and interviews delivered to your inbox. No spam, just valuable information.